文献速递肝胆胰外科

肝移植在肝内胆管癌治疗中的作用

Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation?
PubMed 文献 · Surgery · 2021-12-08

本研究利用美国国家癌症数据库2004至2016年数据,比较肝移植、手术切除与单纯化疗治疗I至III期肝内胆管癌的生存差异。肝移植组5年总生存率与切缘匹配的切除组相当,但显著优于单纯化疗组。

要点

  • 肝移植治疗肝内胆管癌的5年总生存率为36.1%,与切缘匹配的切除组34.7%无显著差异。
  • 肝移植组5年总生存率36.1%显著优于单纯化疗组的5.3%。
  • 肝移植是经选择的局部肝内胆管癌患者的有效治疗方式。

核心结论

  • 肝移植治疗肝内胆管癌的总生存与分期和切缘匹配的手术切除相似。
  • 肝移植是经选择的局部肝内胆管癌患者的有效治疗方式。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库,纳入2004至2016年间组织学确诊的临床I至III期肝内胆管癌患者。
  • 采用倾向性评分匹配建立肝移植、手术切除或单纯化疗的匹配队列,用Kaplan-Meier法比较总生存率。

主要发现

  • 调整分析显示,与手术切除患者相比,肝移植患者更可能为男性(比值比4.35,95%置信区间[0.12, 0.42])、Charlson合并症评分≥2(比值比3.11,95%置信区间[1.44, 6.57])以及接受新辅助(比值比2.78,95%置信区间[1.36, 5.75])和辅助(比值比1.94,95%置信区间[0.97, 3.87])全身治疗。
  • Kaplan-Meier分析显示,肝移植患者的5年总生存率为36.1%,与分期和切缘匹配的手术切除患者的34.7%相比无统计学差异(P = .53)。
  • 肝移植患者的5年总生存率36.1%显著优于分期匹配的单纯全身治疗患者的5.3%(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver transplantation offers a potential for curative-intent treatment in patients presenting with non-metastatic intrahepatic cholangiocarcinoma that is not amenable to partial hepatectomy. There is little empiric evidence evaluating the efficacy of liver transplantation in patients with intrahepatic cholangiocarcinoma. METHODS: We queried the National Cancer Database to identify patients presenting with histologically confirmed clinical stage I to III intrahepatic cholangiocarcinoma between 2004 and 2016. Propensity scoring was used to develop matched cohorts of patients undergoing treatment with liver transplantation, surgical resection, or chemotherapy alone. Kaplan Meier methods were used to compare rates of overall survival. RESULTS: One thousand four hundred and eleven patients met inclusion criteria. Of these, 66 (4.7%) underwent liver transplantation, 461 (32.7%) underwent surgical resection, and 884 (62.6%) were treated with chemotherapy alone. On adjusted analysis, patients undergoing liver transplantation were more likely to be male (odds ratio 4.35, 95% confidence interval [0.12, 0.42]), have a Charlson Comorbidity Score ≥2 (odds ratio 3.11, 95% confidence interval [1.44, 6.57]), and to receive both neoadjuvant (odds ratio 2.78, 95% confidence interval [1.36,5.75], and adjuvant (odds ratio 1.94, 95% confidence interval [0.97, 3.87]) systemic therapy than those undergoing resection. On Kaplan Meier analysis, patients undergoing liver transplantation demonstrated rates of 5-year overall survival (36.1% vs 34.7%, P = .53) that were statistically identical to those for stage-matched and margin-matched patients undergoing resection but significantly better than those for stage-matched patients treated with systemic therapy alone (36.1% vs 5.3%, P < .0001). CONCLUSION: Patients undergoing liver transplantation for intrahepatic cholangiocarcinoma demonstrate overall survival profiles similar to stage-matched and margin-matched patients undergoing surgical resection. Liver transplantation is an effective treatment modality in select patients presenting with localized intrahepatic cholangiocarcinoma.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kim P, Littau M, Baker TB, et al. Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation? Surgery. 2021. PMID: 34895770. doi:10.1016/j.surg.2021.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。